Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metoprolol + spironolactone + empagliflozin
- Development stage
- Unknown
- Lead developer
- UT Southwestern Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
metoprolol + spironolactone + empagliflozin is an investigational, unapproved once-daily fixed-dose combination "polypill" developed by the University of Texas Southwestern Medical Center for the treatment of heart failure with reduced ejection fraction (HFrEF). It combines three guideline-directed medical therapies (GDMT) into a single capsule: metoprolol succinate (a beta-1 adrenergic receptor blocker), spironolactone (a mineralocorticoid receptor antagonist), and empagliflozin (a sodium-glucose cotransporter 2 inhibitor). In the Phase 2 POLY-HF trial, the polypill was manufactured by over-encapsulating the separate drugs in an inert gel capsule. The combination is designed to simplify complex medication regimens, reduce pill burden, and improve treatment adherence and clinical outcomes in patients with HFrEF.
- Other names
- metoprolol succinate + spironolactone + empagliflozinPOLY-HF polypill
02
Targets
ADRB1 (β1)MR (Mineralocorticoid receptor)PR (Progesterone receptor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on metoprolol + spironolactone + empagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metoprolol + spironolactone + empagliflozin.